ly 243670 has been researched along with naltrexone in 4 studies
| Studies (ly 243670) | Trials (ly 243670) | Recent Studies (post-2010) (ly 243670) | Studies (naltrexone) | Trials (naltrexone) | Recent Studies (post-2010) (naltrexone) |
|---|---|---|---|---|---|
| 14 | 0 | 2 | 8,745 | 1,228 | 2,642 |
| Protein | Taxonomy | ly 243670 (IC50) | naltrexone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0051 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0063 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.006 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.006 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.0319 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0093 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0377 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0076 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shaw, WN | 1 |
| Emmerson, PJ; McKinzie, JH; Mitch, CH; Statnick, MA; Surface, PL; Suter, TM | 1 |
| Gackenheimer, SL; Gehlert, DR; Mitch, CH; Pintar, JE; Quimby, SJ; Statnick, MA; Suter, TM; Wheeler, WJ | 1 |
| Bell, RL; Dhaher, R; Hauser, SR; McBride, WJ; McKinzie, DL; Rodd, ZA; Toalston, JE | 1 |
4 other study(ies) available for ly 243670 and naltrexone
| Article | Year |
|---|---|
Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants.
Topics: Albuterol; Animals; Appetite Depressants; Cyclohexanes; Dextroamphetamine; Drug Tolerance; Eating; Endorphins; Female; Fenfluramine; Injections, Subcutaneous; Male; Naltrexone; Obesity; Piperidines; Rats; Rats, Zucker; Weight Gain | 1993 |
Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists.
Topics: Animals; Appetite Depressants; Binding, Competitive; Cell Membrane; CHO Cells; Cricetinae; Cyclohexanes; Diprenorphine; Dose-Response Relationship, Drug; Eating; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Guanosine 5'-O-(3-Thiotriphosphate); Ligands; Naltrexone; Narcotic Antagonists; Piperidines; Radioligand Assay; Rats; Rats, Zucker; Receptors, Opioid; Receptors, Opioid, delta; Sodium | 2004 |
Localization of opioid receptor antagonist [3H]-LY255582 binding sites in mouse brain: comparison with the distribution of mu, delta and kappa binding sites.
Topics: Animals; Autoradiography; Binding Sites; Brain; Cyclohexanes; Mice; Mice, Knockout; Molecular Structure; Naloxone; Naltrexone; Narcotic Antagonists; Piperidines; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Tritium | 2005 |
Effects of naltrexone and LY255582 on ethanol maintenance, seeking, and relapse responding by alcohol-preferring (P) rats.
Topics: Alcohol Drinking; Animals; Central Nervous System Depressants; Conditioning, Operant; Cyclohexanes; Drug-Seeking Behavior; Ethanol; Extinction, Psychological; Female; Naltrexone; Narcotic Antagonists; Piperidines; Rats; Secondary Prevention | 2012 |